8-K: KALA BIO Announces Third Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO reported its third quarter 2024 financial results, highlighting progress in its Phase 2b CHASE trial for KPI-012 and providing a corporate update.

Summary

• KALA BIO announced its financial results for the third quarter ended September 30, 2024, and provided a corporate update.
• The company is focused on advancing patient enrollment in the Phase 2b CHASE trial for KPI-012, with topline results expected in the second quarter of 2025.
• Five clinical trial sites have been initiated in Argentina for the CHASE trial, with additional sites in Latin America in process.
• KALA's lead product candidate, KPI-012, is being developed for the treatment of Persistent Corneal Epithelial Defect (PCED), which has an estimated incidence of 100,000 patients in the U.S.
• The company believes the CHASE trial could potentially serve as the first of two pivotal studies required for a Biologics License Application (BLA) submission to the FDA.
• KALA is also exploring KPI-012 for other rare eye diseases, including Limbal Stem Cell Deficiency (LSCD), which also has an estimated incidence of 100,000 patients in the U.S.
• KALA's preclinical program, KPI-014, is being evaluated for inherited retinal degenerative diseases.
• As of September 30, 2024, KALA had $49.2 million in cash and cash equivalents.
• The company anticipates its cash resources will fund operations into the fourth quarter of 2025.
• For the quarter ended September 30, 2024, the net loss was $9.0 million, or $1.93 per share, compared to a net loss of $8.7 million, or $3.41 per share, for the same period in 2023.
• For the nine months ended September 30, 2024, the net loss was $30.3 million, or $8.68 per share, compared to a net loss of $33.6 million, or $14.36 per share, for the same period in 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, the potential of KPI-012, and the cash runway into late 2025. However, the ongoing losses and risks associated with clinical development temper the overall sentiment.

Positives

• The company is making progress in its Phase 2b CHASE trial for KPI-012.
• KALA has initiated clinical trial sites in Argentina and is expanding to other Latin American countries.
• KPI-012 has the potential to be a first-in-class treatment for PCED.
• The company has a strong cash position of $49.2 million.
• KALA anticipates its cash resources will fund operations into the fourth quarter of 2025.
• The net loss per share decreased for both the three and nine month periods compared to the same periods in 2023.

Negatives

• The company experienced an operating loss of $10.0 million for the quarter ended September 30, 2024.
• The company experienced an operating loss of $31.5 million for the nine months ended September 30, 2024.
• The company's cash position decreased from $54.2 million as of June 30, 2024, to $49.2 million as of September 30, 2024.

Risks

• The company's ability to comply with the requirements under the CIRM award is a risk.
• There are uncertainties inherent in the initiation and conduct of preclinical studies and clinical trials.
• The availability and timing of data from clinical trials is uncertain.
• There is a risk that results of early clinical trials may not be indicative of the results of ongoing or future trials.
• Regulatory review of clinical trials and applications for marketing approvals is uncertain.
• The company's ability to retain and hire key personnel is a risk.
• The company's ability to comply with the covenants under its loan agreement is a risk.
• The company may need additional financing in the future.

Future Outlook

KALA anticipates that its cash resources as of September 30, 2024, and anticipated additional funding under the CIRM award, will enable it to fund operations into the fourth quarter of 2025. The company also plans to report topline data from the CHASE Phase 2b trial in the second quarter of 2025.

Management Comments

• Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, stated that they remain focused on advancing patient enrollment in the Phase 2b CHASE trial and are targeting topline results in the second quarter of 2025.
• Mark Iwicki also stated that they believe KPI-012 has the potential to be a first-in-class treatment for PCED.

Industry Context

KALA BIO is operating in the biopharmaceutical industry, specifically focusing on rare and severe eye diseases. The company's focus on developing treatments for conditions like PCED and LSCD, which have significant unmet medical needs, aligns with the industry trend of targeting orphan diseases. The use of a mesenchymal stem cell secretome (MSC-S) platform is an innovative approach in the field of regenerative medicine.

Comparison to Industry Standards

• KALA BIO's focus on rare ophthalmic diseases is similar to companies like REGENXBIO and MeiraGTx, which are also developing gene therapies for inherited retinal diseases.
• The development of KPI-012 for PCED is unique as there are currently no FDA-approved prescription products with a broad indication covering all underlying etiologies of PCED, setting KALA apart from competitors in this specific area.
• The company's cash runway into the fourth quarter of 2025 is a positive sign, but it will need to continue to raise capital to fund its clinical programs, similar to other clinical-stage biotech companies.
• The reported net losses are typical for a clinical-stage biotech company that is investing heavily in research and development, and are comparable to other companies in the sector at a similar stage of development.

Stakeholder Impact

• Shareholders will be interested in the progress of the clinical trials and the company's financial position.
• Employees will be impacted by the company's ability to continue funding operations.
• Patients with PCED and other rare eye diseases will be impacted by the potential development of new treatments.
• Creditors will be interested in the company's ability to repay its debts.

Next Steps

• KALA will continue to enroll patients in the Phase 2b CHASE trial.
• The company plans to report topline data from the CHASE trial in the second quarter of 2025.
• KALA will continue to explore the potential of KPI-012 for other rare eye diseases.
• The company will continue preclinical studies for KPI-014 for inherited retinal diseases.

Key Dates

Keywords

KALA BIO, KPI-012, PCED, CHASE trial, MSC-S platform, clinical trial, biopharmaceutical, ophthalmology, rare diseases, financial results